Scynexis clinches FDA green light for vaginal yeast infection blockbuster-to-be

Armed with an approval in a prominent condition with few attractive treatment options, Scynexis is preparing to make a big splash in women's health.

The FDA this week approved Scynexis’ ibrexafungerp tablets, now christened Brexafemme, to treat vaginal yeast infections. The green light marks the first approval in a new class of antifungal drugs in more than 20 years and propels Scynexis into the commercial realm with a potential blockbuster in tow.